Literature DB >> 9930458

Comparison of different anticalcification treatments for stentless bioprostheses.

T Walther1, V Falk, R Autschbach, A Diegeler, T Rauch, C Weigl, B Günther, J A van Son, F W Mohr.   

Abstract

BACKGROUND: New anticalcificant treatments have been developed because tissue calcification is a major contributing factor for bioprosthetic valve failure.
METHODS: Aortic valve leaflet and aortic root tissue samples from stentless bioprostheses treated with No-React (Biocor, Belo Horizonte, Brazil), AOA (Medtronic freestyle, Minneapolis, MN), and BiLinx (St. Jude Medical, St. Paul, MN) were compared to a control group by subcutaneous implantation in 60 male weanling Sprague-Dawley rats.
RESULTS: Calcium levels were in the range of 0.3 to 2.2 mg/g dry tissue at 3 and 12 weeks in all three treated aortic valve leaflet implants. The BiLinx treatment proved anticalcificant effectiveness on aortic root samples as well. There were statistically significant differences for valve leaflet tissue samples: No-React = AOA < BiLinx < < Control and for aortic root tissue samples: BiLinx < < AOA < Control = No-React.
CONCLUSION: Calcification of aortic valve leaflets was significantly reduced by all new anticalcificant treatments. Inhibition of cellular calcification (BiLinx) resulted in additional reduction of aortic root calcification. Maximum anticalcificant properties upon both leaflet and aortic root is important as these are considered a functional unit in stentless bioprostheses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930458     DOI: 10.1016/s0003-4975(98)00985-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis.

Authors:  Robert J M Klautz; A Pieter Kappetein; Rüdiger Lange; Francois Dagenais; Louis Labrousse; Vinayak Bapat; Michael Moront; Martin Misfeld; Cathy Zeng; Joseph F Sabik Iii
Journal:  Eur J Cardiothorac Surg       Date:  2017-09-01       Impact factor: 4.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.